First notice of allowance of patent and top-line results from PK study of VAL001 available
Respiratorius announces that the patent application for the formulation of VAL001 has been allowed by a formal notice of allowance from Japan Patent Office. Respiratorius also announces that preliminary top-line results from the PK study with VAL001 are available.The patent application, claiming a novel and dedicated oral formulation of sodium valproate for pretreating cancer, has been allowed by the Japan Patent Office. The priority date of the patent application is 21 April 2016 and in force for at least 20 years from the priority date granting market exclusivity. The tailored